S147: EFFICACY AND SAFETY RESULTS OF MOLTO, A MULTICENTER, OPEN LABEL, PHASE II CLINICAL TRIAL EVALUATING VENETOCLAX, ATEZOLIZUMAB AND OBINUTUZUMAB COMBINATION IN RICHTER SYNDROME

por Frustaci, Anna Maria, Montillo, Marco, Rossi, Davide, Zinzani, Pier Luigi, Motta, Marina, Gaidano, Gianluca, Quaresmini, Giulia, Scarfò, Lydia, Pietrasanta, Daniela, Coscia, Marta, Deodato, Marina, Zamprogna, Giulia, Cairoli, Roberto, Stüssi, Georg, Zucca, Emanuele, Pileri, Stefano, Zenz, Thorsten, Tedeschi, Alessandra
Publicado 2023

COVID-19 Vaccination in Fragile Patients: Current Evidence and an Harmonized Transdisease Trial

por Agrati, Chiara, Di Cosimo, Serena, Fenoglio, Daniela, Apolone, Giovanni, Ciceri, Fabio, Ciliberto, Gennaro, Baldanti, Fausto, Costantini, Massimo, Giannarelli, Diana, Ippolito, Giuseppe, Locatelli, Franco, Mantovani, Alberto, Morrone, Aldo, Tagliavini, Fabrizio, Uccelli, Antonio, Zinzani, Pier Luigi, Silvestris, Nicola, Rescigno, Maria
Publicado 2021

Safety of third dose of COVID-19 vaccination in frail patients: Results from the prospective Italian VAX4FRAIL study

por Di Cosimo, Serena, Lupo-Stanghellini, Maria Teresa, Costantini, Massimo, Mantegazza, Renato, Ciceri, Fabio, Salvarani, Carlo, Zinzani, Pier Luigi, Mantovani, Alberto, Ciliberto, Gennaro, Uccelli, Antonio, Baldanti, Fausto, Apolone, Giovanni, Delcuratolo, Sabina, Morrone, Aldo, Locatelli, Franco, Agrati, Chiara, Silvestris, Nicola
Publicado 2022

Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma: final analysis of KEYNOTE-170

por Zinzani, Pier Luigi, Thieblemont, Catherine, Melnichenko, Vladimir, Bouabdallah, Krimo, Walewski, Jan, Majlis, Alejandro, Fogliatto, Laura, Garcia-Sancho, A. Martin, Christian, Beth, Gulbas, Zafer, Özcan, Muhit, Perini, Guilherme Fleury, Ghesquieres, Herve, Shipp, Margaret A., Thompson, Seth, Chakraborty, Samhita, Marinello, Patricia, Armand, Philippe
Publicado 2023

Is Good Clinical Practice Becoming Poor Clinical Care?

por Le Gouill, Steven, Dreyling, Martin, Caballero, Maria Dolores, Andre, Marc, Doorduijn, Jeannette, Jurczak, Wojciech, Jerkeman, Mats, Ghia, Paolo, Zinzani, Pier-Luigi, Da Silva, Maria Gomez, Dimopoulos, Meletios, Trneny, Marek, Delarue, Richard, Walewski, Jan, Gisselbrecht, Christian, López-Guillermo, Armando, Rule, Simon
Publicado 2017

High Humoral Response after Anti-Sars-Cov-2 mRNA-Based Vaccines in Patients with Active Multiple Myeloma (MM) and Relationship with Disease Status/Line of Therapy

por Mancuso, Katia, Zamagni, Elena, Solli, Vincenza, Gabrielli, Liliana, Pantani, Lucia, Rocchi, Serena, Rizzello, Ilaria, Tacchetti, Paola, Fusco, Alessio, De Cicco, Gabriella, Ursi, Margherita, Talarico, Marco, Favero, Emanuele, Nepoti, Giuliana, Ruffini, Barbara, Terragna, Carolina, Lazzarotto, Tiziana, Zinzani, Pier Luigi, Cavo, Michele
Publicado 2021

RE-MIND: Comparing Tafasitamab + Lenalidomide (L-MIND) with a Real-world Lenalidomide Monotherapy Cohort in Relapsed or Refractory Diffuse Large B-cell Lymphoma

por Zinzani, Pier Luigi, Rodgers, Thomas, Marino, Dario, Frezzato, Maurizio, Barbui, Anna Maria, Castellino, Claudia, Meli, Erika, Fowler, Nathan H., Salles, Gilles, Feinberg, Bruce, Kurukulasuriya, Nuwan C., Tillmanns, Sascha, Parche, Stephan, Dey, Debarshi, Fingerle-Rowson, Günter, Ambarkhane, Sumeet, Winderlich, Mark, Nowakowski, Grzegorz S.
Publicado 2021

Case report: Senescence as mechanism of resistance to Pembrolizumab in a Lymphoma patient who failed CD19-Targeted CAR-T cell therapy

por De Matteis, Serena, Casadei, Beatrice, Lolli, Ginevra, Dicataldo, Michele, Barbato, Francesco, Dan, Elisa, Paccagnella, Andrea, Sinigaglia, Barbara, Bertuzzi, Clara, Arcari, Annalisa, Zazzeroni, Luca, Bernuzzi, Patrizia, Laprovitera, Noemi, Storci, Gianluca, Bertuccio, Salvatore Nicola, Ferracin, Manuela, Bonafè, Massimiliano, Zinzani, Pier Luigi, Bonifazi, Francesca
Publicado 2022

Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial

por Kreitman, Robert J., Dearden, Claire, Zinzani, Pier Luigi, Delgado, Julio, Robak, Tadeusz, le Coutre, Philipp D., Gjertsen, Bjørn T., Troussard, Xavier, Roboz, Gail J., Karlin, Lionel, Gladstone, Douglas E., Kuptsova-Clarkson, Nataliya, Liu, Shiyao, Patel, Priti, Rotolo, Federico, Mitry, Emmanuel, Pastan, Ira, Giles, Francis
Publicado 2021

Improved Efficacy of Tafasitamab plus Lenalidomide versus Systemic Therapies for Relapsed/Refractory DLBCL: RE-MIND2, an Observational Retrospective Matched Cohort Study

por Nowakowski, Grzegorz S., Yoon, Dok Hyun, Peters, Anthea, Mondello, Patrizia, Joffe, Erel, Fleury, Isabelle, Greil, Richard, Ku, Matthew, Marks, Reinhard, Kim, Kibum, Zinzani, Pier Luigi, Trotman, Judith, Huang, Dan, Waltl, Eva E., Winderlich, Mark, Kurukulasuriya, Nuwan C., Ambarkhane, Sumeet, Hess, Georg, Salles, Gilles
Publicado 2022

RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) b...

por Nowakowski, Grzegorz S., Yoon, Dok Hyun, Mondello, Patrizia, Joffe, Erel, Peters, Anthea, Fleury, Isabelle, Greil, Richard, Ku, Matthew, Marks, Reinhard, Kim, Kibum, Zinzani, Pier Luigi, Trotman, Judith, Sabatelli, Lorenzo, Waltl, Eva E., Winderlich, Mark, Sporchia, Andrea, Kurukulasuriya, Nuwan C., Cordoba, Raul, Hess, Georg, Salles, Gilles
Publicado 2023

Correction to: RE‑MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola‑BR), CAR‑T therapies, and lenalidomide/r...

por Nowakowski, Grzegorz S., Yoon, Dok Hyun, Mondello, Patrizia, Joffe, Erel, Peters, Anthea, Fleury, Isabelle, Greil, Richard, Ku, Matthew, Marks, Reinhard, Kim, Kibum, Zinzani, Pier Luigi, Trotman, Judith, Sabatelli, Lorenzo, Waltl, Eva E., Winderlich, Mark, Sporchia, Andrea, Kurukulasuriya, Nuwan C., Cordoba, Raul, Hess, Georg, Salles, Gilles
Publicado 2023

Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphoma

por Armand, Philippe, Zinzani, Pier Luigi, Lee, Hun Ju, Johnson, Nathalie A., Brice, Pauline, Radford, John, Ribrag, Vincent, Molin, Daniel, Vassilakopoulos, Theodoros P., Tomita, Akihiro, von Tresckow, Bastian, Shipp, Margaret A., Herrera, Alex F., Lin, Jianxin, Kim, Eunhee, Chakraborty, Samhita, Marinello, Patricia, Moskowitz, Craig H.
Publicado 2023

Dual targeting of the DNA damage response pathway and BCL-2 in diffuse large B-cell lymphoma

por Rossi, Alessandra, Orecchioni, Stefania, Falvo, Paolo, Tabanelli, Valentina, Baiardi, Elena, Agostinelli, Claudio, Melle, Federica, Motta, Giovanna, Calleri, Angelica, Fiori, Stefano, Corsini, Chiara, Casadei, Beatrice, Mazzara, Saveria, Vitolo, Umberto, Bertolini, Francesco, Zinzani, Pier Luigi, Alcalay, Myriam, Pelicci, Pier Giuseppe, Pileri, Stefano, Tarella, Corrado, Derenzini, Enrico
Publicado 2021

Quality-of-life analysis of pembrolizumab vs brentuximab vedotin for relapsed/refractory classical Hodgkin lymphoma

por Zinzani, Pier Luigi, Ramchandren, Radhakrishnan, Santoro, Armando, Paszkiewicz-Kozik, Ewa, Gasiorowski, Robin, Johnson, Nathalie A., de Oliveira, Jose S. R., Buccheri, Valeria, Perini, Guilherme Fleury, Dickinson, Michael, McDonald, Andrew, Özcan, Muhit, Sekiguchi, Naohiro, Zhu, Ying, Raut, Monika, Saretsky, Todd L., Nahar, Akash, Kuruvilla, John
Publicado 2022

mRNA-COVID19 Vaccination Can Be Considered Safe and Tolerable for Frail Patients

por Lupo-Stanghellini, Maria Teresa, Di Cosimo, Serena, Costantini, Massimo, Monti, Sara, Mantegazza, Renato, Mantovani, Alberto, Salvarani, Carlo, Zinzani, Pier Luigi, Inglese, Matilde, Ciceri, Fabio, Apolone, Giovanni, Ciliberto, Gennaro, Baldanti, Fausto, Morrone, Aldo, Sinno, Valentina, Locatelli, Franco, Notari, Stefania, Turola, Elena, Giannarelli, Diana, Silvestris, Nicola
Publicado 2022

P107: Effect of Brentuximab Vedotin Addition to Chemotherapy and Prognostic Factors in Patients with Relapsed/Refractory Hodgkin Lymphoma: a Large Multi-Trial Analysis Based on Ind...

por Driessen, Julia, De Wit, Fer, Herrera, Alex F., Zinzani, Pier Luigi, Lacasce, Ann S., Cole, Peter D., Moskowitz, Craig H., Sanz, Ramón. García, Fuchs, Michael, Müller, Horst, Borchmann, Peter, Santoro, Armando, Schöder, Heiko, Zijlstra, Josée. M., Hutten, Barbara A., Moskowitz, Alison J., Kersten, Marie José
Publicado 2022

Impact of COVID-19 Pandemic Waves on Outcomes of Patients with Previously Untreated Advanced Follicular Lymphoma Enrolled in the Urban Ambispective Study in Italy

por Pinto, Antonio, Guardalben, Emanuele, Battista, Marica, Gazzoli, Giulia Chiara, Merli, Michele, Chiarenza, Annalisa, Perrone, Tommasina, Guarini, Attilio, Di Renzo, Nicola, Visco, Carlo, Tafuri, Agostino, Murru, Roberta, Ferrara, Felicetto, Olivieri, Jacopo, Olivieri, Attilio, Ferreri, Andrés J M, Ladetto, Marco, Zinzani, Pier Luigi, Arcaini, Luca, Gritti, Giuseppe
Publicado 2022

Peripheral blood cellular profile at pre-lymphodepletion is associated with CD19-targeted CAR-T cell-associated neurotoxicity

por De Matteis, Serena, Dicataldo, Michele, Casadei, Beatrice, Storci, Gianluca, Laprovitera, Noemi, Arpinati, Mario, Maffini, Enrico, Cortelli, Pietro, Guarino, Maria, Vaglio, Francesca, Naddeo, Maria, Sinigaglia, Barbara, Zazzeroni, Luca, Guadagnuolo, Serafina, Tomassini, Enrica, Bertuccio, Salvatore Nicola, Messelodi, Daria, Ferracin, Manuela, Bonafè, Massimiliano, Zinzani, Pier Luigi, Bonifazi, Francesca
Publicado 2023

Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory mantle cell lymphoma (CITADEL-205): a phase 2 study

por Zinzani, Pier Luigi, Trněný, Marek, Ribrag, Vincent, Zilioli, Vittorio Ruggero, Walewski, Jan, Christensen, Jacob Haaber, Delwail, Vincent, Rodriguez, Guillermo, Venugopal, Parameswaran, Coleman, Morton, Dartigeas, Caroline, Patti, Caterina, Pane, Fabrizio, Jurczak, Wojciech, Taszner, Michal, Paneesha, Shankara, Zheng, Fred, DeMarini, Douglas J., Jiang, Wei, Gilmartin, Aidan, Mehta, Amitkumar
Publicado 2023